Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Woes May Provide Respite For Drugs Frequently Targeted In Litigation

This article was originally published in The Pink Sheet Daily

Executive Summary

The uproar over COX-2 inhibitors may provide an upside for other drugs that are longstanding litigation targets, such as Lilly's atypical antipsychotic Zyprexa

You may also be interested in...



Pfizer Celebrex Polyp Trial Shows Increase In Cardiovascular Events

The Adenoma Prevention with Celecoxib trial found an increased CV risk for patients taking 400 mg and 800 mg Celebrex compared to placebo; a second study showed no increased risk. The APC study results mean Pfizer can no longer promote the COX-2 as being clear of cardiovascular signals.

Bextra Contraindicated In CABG Surgery Patients

Labeling change to add "black box" for serious skin reactions incorporates post-surgery safety data, including results from two coronary artery bypass graft trials that show increased cardiovascular risk with Pfizer's COX-2 inhibitor.

FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal

Arcoxia's user fee date is Oct. 30, but FDA could decide to wait for 18-month cardiovascular safety data from a 20,000-patient trial comparing etoricoxib with diclofenac. Merck says it will work with regulatory authorities in 47 countries where Arcoxia is marketed to discuss potential labeling changes resulting from the Vioxx study data.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel